Srinivas Akkaraju

Founder at Samsara Biocapital LLC

Srinivas Akkaraju

Srinivas Akkaraju

Founder at Samsara Biocapital LLC

Overview
Career Highlights

Samsara Biocapital LLC
Panorama Capital LLC

RelSci Relationships

640

Number of Boards

20

Birthday

1968

Age

50

Number of Awards

2

Relationships
RelSci Relationships are individuals Srinivas Akkaraju likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Baker Bros. Advisors LP

Relationship likelihood: Strong

Director at Sarcoma Foundation of America

Relationship likelihood: Strong

Co-Founder at Panorama Capital LLC

Relationship likelihood: Strong

President, Chief Executive Officer, Chief Financial Officer & Director at Versartis, Inc.

Relationship likelihood: Strong

Partner at New Leaf Venture Partners LLC

Relationship likelihood: Strong

President & Chief Executive Officer at Principia Biopharma, Inc.

Relationship likelihood: Strong

Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Syros Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Seattle Genetics, Inc.

Relationship likelihood: Strong

Co-Founder at Intercept Pharmaceuticals, Inc.

Relationship likelihood: Strong

Paths to Srinivas Akkaraju
Potential Connections via
Relationship Science
You
Srinivas Akkaraju
Founder at Samsara Biocapital LLC
Education
MD in Immunology

A LEADER IN THE BIOMEDICAL REVOLUTION, Stanford Medicine has a long tradition of leadership in pioneering research, creative teaching protocols and effective clinical therapies. Our close proximity to the resources of the university—including the Schools of Business, Law, Humanities and Sciences and Engineering—our seamless relationship with our affiliated adult and children’s hospitals and our ongoing associations with the entrepreneurial endeavors of Silicon Valley make us uniquely positioned to accelerate the pace at which new knowledge is turned into tangible health benefits.

BA in Computer Science

Rice University is a comprehensive research university that fosters diversity and an intellectual environment that produces the next generation of leaders and advances tomorrow’s thinking and is set in the heart of Houston, Texas, the nation’s fourth-largest city.

Career History
Founder
2016 - Current
General Partner
2013 - Prior

Sofinnova is a clinical-stage biopharmaceutical venture capital firm focused on life science and information technology. They specializes in clinical and late preclinical investments in biopharmaceutical products and partner with entrepreneurs across all stages of company formation including securing initial funding, building successful management teams, forming impactful corporate alliances, and navigating the M&A acquisition or IPOs' process. Sofinnova invests in companies in the US and Europe that do business in the US, Israel, India, China, Japan and Europe.

Managing Director
2009 - 2013

New Leaf Ventures Partners focuses exclusively in healthcare companies located in the US with strong management teams and revenues exceeding $100 million. They targets companies operating in the fields of biopharmaceutical, information convergence (HCIT), medical device and life science tools. The firm provides financing for early and later stage capital requirements and invests in both public & private companies.

Boards & Committees
Member, Board of Directors
2017 - Current

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The company focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. Syros Pharmaceuticals was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Member, Board of Directors
2015 - Current

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of innovative therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler in 2005 and is headquartered in San Diego, CA.

Chairman, Board of Directors
2013 - Current

Versartis, Inc. engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA.

Director
Current

The George Institute for Global Health provides research and development for international health. It develops tools to empower people to improve their own health. The firm also uses mobile technology to make healthcare accessible worldwide and improves outcomes among stroke survivors. It helps preventing complications of diabetes. The company was founded by Stephen MacMahon and Robyn Norton in 1999 and is headquartered in Sydney, Australia.

Political Donations
$1,300
2010
$1,400
2009
$1,000
2008
Transactions
Details Hidden

SOFINNOVA VENTURE PARTNERS IX, L.P. raised money in a private placement transaction

Investments
Details Hidden

PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK.

Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
Rank #84
2007
Forbes Magazine - The Midas List
Rank #82
2006
Forbes Magazine - The Midas List